• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Study investigates management strategies for intermediate to high-risk prostate cancer


“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.

In this video, Bridget F. Koontz, MD, discusses the background, findings, and takeaways of the study, “Five year results of short course complete androgen blockade with abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high risk prostate cancer,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. She also reports updates in GenesisCare technologies related to prostate cancer. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.

Related Videos
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
David Barquin, MD, answers a question during a Zoom video interview
Alexandra Tabakin, MD, answers a question during a Zoom video interview
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.